Dr. Matthew SchuchertThoracic Surgeon
Dr. Matthew Schuchert is board-certified in thoracic surgery with a specialization in cardiothoracic vascular surgery. He is an assistant professor in the University of Pittsburgh Hillman Cancer Center’s Department of Cardiothoracic Surgery.
For Matthew Schuchert, fighting lung cancer calls for a multi-faceted treatment plan, one that places research and training on equal footing with actual treatment options in the operating room. Fortunately, Schuchert’s education and career progression places him in the ideal position to advance his many investigations into the causes and behaviors of cancer while employing the latest surgical techniques to benefit his patients.
A thoracic surgeon, Schuchert completed his undergraduate studies at Yale University and received his medical degree at Johns Hopkins University School of Medicine. He then completed a residency in general surgery at the University of Pittsburgh School of Medicine, followed by a fellowship in minimally invasive thoracic and foregut surgery at the University of Pittsburgh Medical Center (UPMC).
Within the UPMC’s network of cancer treatment facilities, Hillman Cancer Center stands out as a premier treatment destination for lung cancer and mesothelioma patients with localized diseases. As such, Schuchert and his team of medical professionals at the Lung Cancer Program have direct access to the latest studies and research findings, as well as state-of-the-art equipment and facilities. With this access, Schuchert can provide his patients with the full spectrum of clinical services and procedures, both proven and experimental, offered by the UPMC Cancer Centers and the University of Pittsburgh Cancer Institute.
Focusing on Lungs
In his surgical practice, Schuchert emerged as an expert in thoracic surgical oncology, focusing on lung cancer, asbestos-related cancer, esophageal cancer and other conditions affecting the heart and lungs and their associated organs. He is one of several thoracic surgical oncologists that treats mesothelioma in the Lung Cancer Program. Schuchert prefers minimally invasive surgical procedures for his patients, taking full advantage of cutting-edge technologies, such as radiofrequency ablation and the CyberKnife, a radiosurgery system that focuses high-intensity radiation to directly target and eradicate lesions.
Over the course of his education and studies, Schuchert gained extensive knowledge on the immunology and tumor biology of lung cancer through research projects and clinical trials. Along with colleagues, Schuchert published numerous clinical reports on lung and esophageal cancer in peer-reviewed surgical journals. He is a member of many surgical societies including the Society of Thoracic Surgeons, the Society of University Surgeons and the American College of Surgeons.
Schuchert’s current research aims to help us better understand how the immune system can influence outcomes in lung cancer. His work centers on the study of T cells and Dendritic Cell subsets, immune cells that may have important roles in donor-specific transplantation tolerance and anti-tumor immunity. The goal is to provide critical information about the use of stem-cell therapy in various settings, including transplantation and tissue regeneration.